The study for clinical usefulness of the cross-linked N-telopeptide of type I collagen as a marker of denosumab treatment of bone metastasis from lung cancer

The study for clinical usefulness of the cross-linked N-telopeptide of type I collagen as a marker of denosumab treatment of bone metastasis from lung cancer - The study for clinical usefulness of the NTx as a marker for denosumab treatment from lung cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013752

Enrollment

Registered

2014-04-18

Start date

2014-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer with bone metastasis

Interventions

1:Severrity of symptoms of bone metastasis in bone scintigraphy and comparative study of NTx 2-1:Utility examination of NTX in monitor of therapeutic gain after bone metastasis is diagnosed and bone

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: advanced lung cancer with bone metastasis

Exclusion criteria

Exclusion criteria: 1:Patient who judged that research representative or allotment researcher is improper 2:Bisphosphonate administering patient 3:Metabolic bone disease patient 4:Kidney function deterioration patient 5:treatment for lung cancer in the past

Design outcomes

Primary

Measure	Time frame
1:Utility examination of NTX in monitor of therapeutic gain after bone metastasis is diagnosed and bone metastasis progress level 2:Utility of bone metastasis index	—

Countries

Japan

Contacts

Public ContactTamiya Motohiro

Osaka prefectural Medical Center for Respiratory and Allergic Diseases Thoracic Malignancy

moto19781205@yahoo.co.jp+81-729-57-2121

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026